Đăng xuất
Growth retardation in children who were born small for gestational age
Child: In children with no catch-up growth by 2-4 years of age: 0.035-0.070 mg/kg once daily. May initiate doses at the higher end of the dosing range in patients with significant growth retardation. Alternatively, up to 0.48 mg/kg weekly, divided in 6 or 7 doses a week. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Subcutaneous
Growth retardation due to chronic renal insufficiency
Child: 0.045-0.05 mg/kg daily. Alternatively, 0.35 mg/kg weekly, divided into daily inj. Continue treatment until the time of renal transplantation. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Subcutaneous
Prader-Willi syndrome
Child: Approx 0.035 mg/kg or 1 mg/m2 daily (Max: 2.7 mg daily). Alternatively, 0.24 mg/kg weekly, divided daily into 6 or 7 doses a week. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Subcutaneous
Turner syndrome
Child: 0.045-0.067 mg/kg (0.14 units/kg) daily or 1.3-2 mg/m2 daily. Alternatively, 0.35-0.375 mg/kg weekly, divided into equal doses 7 days a week. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Subcutaneous
Growth hormone deficiency
Adult: Non-weight-based dosing: 0.2-0.4 mg daily; higher doses (e.g. 50% of the dose used in childhood) may be required if transitioning from paediatric treatment. Weight-based dosing: Initially, ≤0.006 mg/kg (0.018 units/kg) daily; may increase gradually according to patient's response. Max: 0.0125 mg/kg daily. Dose is individualised and adjusted according to the patient's clinical and biochemical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Child: 0.025-0.035 mg/kg (0.07-0.1 units/kg) daily or 0.7-1 mg/m2 daily. Alternatively, 0.16-0.24 mg/kg weekly, divided into equal doses 6 or 7 days a week. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Elderly: Initiate at a lower dose with smaller dose increments.
Child: 0.025-0.035 mg/kg (0.07-0.1 units/kg) daily or 0.7-1 mg/m2 daily. Alternatively, 0.16-0.24 mg/kg weekly, divided into equal doses 6 or 7 days a week. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Elderly: Initiate at a lower dose with smaller dose increments.
Subcutaneous
HIV-associated wasting or cachexia
Adult: Initially, 0.1 mg/kg once daily at bedtime. May be given on alternate days for patients at increased risk of adverse effects. Max: 6 mg daily. Dose is individualised and adjusted according to the patient's clinical response and safety. Refer to specific product guidelines for further information.
Subcutaneous
Short stature homeobox-containing gene (SHOX) deficiency
Child: 0.35 mg/kg weekly, divided into equal doses 6 or 7 days a week. Dose is individualised and adjusted according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Subcutaneous
Short bowel syndrome
Adult: 0.1 mg/kg once daily for 4 weeks. Max: 8 mg daily. Dose is individualised and adjusted or discontinued according to patient safety.
Subcutaneous
Short stature associated with Noonan syndrome
Child: Up to 0.066 mg/kg daily. Dose is individualised according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Subcutaneous
Idiopathic short stature
Child: In patients with height standard deviation score of ≤ -2.25 and growth rate unlikely to attain adult height in normal range: Initially, 0.24 mg/kg weekly, divided into equal doses 6-7 days a week; up to 0.47 mg/kg weekly in divided doses may be required in some patients. Dose is individualised according to the patient's clinical response. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
